Skip to Main Content
Skip Nav Destination






(proe METH a zeen)

Brand Names: US

  • Phenadoz [DSC]
  • Phenergan
  • Promethegan

Therapeutic Category

  • Antiemetic
  • Phenothiazine Derivative
  • Sedative

Medication Safety Issues

Sound-alike/look-alike issues:

Promethazine may be confused with chlorproMAZINE, predniSONE

Phenergan may be confused with PHENobarbital, Phrenilin, Theragran

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication (injectable formulation) among its list of drugs that have a heightened risk of causing significant patient harm when used. ISMP strongly discourages use of injectable promethazine (any route) and suggests facilities remove from all areas (including pharmacy) and not allow practitioners to order (ISMP 2020).

Older Adult: High-risk medication:

Beers Criteria: Promethazine, a first-generation antihistamine, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic (Beers Criteria [AGS 2019]).

Pharmacy Quality Alliance (PQA): Promethazine, as a single agent or as part of a combination, is identified as a high-risk medication in patients 65 years and older on the PQA's Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans (PQA 2017).

Pediatric patients: High-risk medication:

KIDs List: Dopamine antagonists, when used in pediatric patients <18 years of age, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided in infants and used with caution in children and adolescents due to risk of acute dystonia (dyskinesia), and with intravenous administration an increased risk of respiratory depression, extravasation, and death (strong recommendation; moderate quality of evidence) (PPA [Meyers 2020]).

International issues:

Sominex: Brand name for promethazine in Great Britain, but also is a brand name for diphenhydrAMINE in the US

This item requires a subscription. For full access to this content, please log in to an existing user account or purchase an individual subscription. If you have an active subscription and appear logged in (your name appears in the upper right corner), but you cannot access content, please click the “Log Out” option under your name and log back in.
Close Modal

or Create an Account

Close Modal
Close Modal